Journal of Vaccines & Vaccination

Immunotherapy of cancer perspectives and challenges in the context of cancer care in the community

10^th Euro Global Summit and Expo on Vaccines & Vaccination

June 16-18, 2016 Rome, Italy

Venumadhav Reddy Kotla

Cookeville Regional Medical Center, USA

Posters & Accepted Abstracts: J Vaccines Vaccin

Abstract:

Immunotherapy of cancer is redefining the paradigm of cancer care. Immunotherapy for cancer is the buzz word nowadays and there seems to be an increasing trend of enthusiasm from patients and community physicians alike. So far therapies like Opdivo (Nivolumumab), Keytruda (Pembrozulimab) and Ipilumumba (Yervoy) have been approved for Melanoma. Opdivo is indicated in treatment of Non-Small Cell Lung Cancer and Renal Cancer as well the role of immunotherapy continues to evolve in terms of a broader application in different cancer types. There is reason to believe that the immunotherapy may ultimately become the backbone of oncology therapies and the traditional chemotherapy as we know currently will be useful as adjunctive therapy. There are implications for immunotherapies in primary prevention, secondary prevention, managing minimal residual disease. With these exciting times in oncology, there are tremendous challenges involved in transitioning these scientific advances into community cancer clinics where 80% of the cancer care is given. The purpose of this talk is to give a broad overview of immunotherapy, illustrating the transition from science in a research lab to a clinic in a rural area, to highlight the challenges associated and to describe some ways to address these challenges, all from a community cancer care perspective. The challenges that we are faced with are the need for education of the patients and community physicians, being able to bridge the limited scientific understanding about these therapies, addressing the cost of care that is disabling to the society, adverse effect management, knowing how to sequence treatments, issues of reimbursement that will ultimately affect the access.

Biography :

Email: venumadhav_kotla@yahoo.com